- Investing Ideas
- /
- Global Buy the Dip
Global Buy the Dip
Results
364
0 new
Companies which have seen a dip in the last 7 days after continued gains and are looking undervalued based on Snowflake checks.
364 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
OB | US$6.07 | -9.9% | 47.0% | US$566.9m | US$8.20 | PE161.4x | E103.1% | n/a | Media | ||
MNMD | US$7.63 | -22.9% | 55.4% | US$559.5m | US$25.60 | PB2.1x | E42.8% | n/a | Pharmaceuticals & Biotech | ||
EMIL B | SEK 46.60 | -9.0% | 36.7% | SEK 5.9b | SEK 55.00 | PE21.8x | E5.6% | n/a | Real Estate Management and Development | ||
603117 | CN¥6.32 | -8.5% | 102.6% | CN¥3.8b | n/a | PS12.7x | n/a | 0% | Transportation | ||
GAMB | US$14.63 | -12.7% | 66.3% | US$513.2m | US$18.86 | PE17.6x | E21.0% | n/a | Media | ||
CCSI | US$25.68 | -10.9% | 52.8% | US$501.4m | US$28.60 | PE5.6x | E5.8% | n/a | Software | ||
DCGO | US$4.79 | -13.5% | 44.7% | US$486.3m | US$6.36 | PE15.8x | E-50.7% | n/a | Healthcare | ||
7685 | JP¥2,524.00 | -10.5% | 71.0% | JP¥72.3b | JP¥3,537.50 | PE30x | E27.0% | 0.6% | Retail | ||
OTB | UK£2.37 | -8.3% | 63.1% | UK£380.0m | UK£2.96 | PE18.8x | E20.7% | 1.3% | Consumer Services | ||
DCTH | US$14.88 | -8.6% | 244.4% | US$475.8m | US$21.83 | PS21x | E58.1% | n/a | Healthcare | ||
NWPX | US$47.81 | -9.1% | 64.6% | US$474.2m | US$56.33 | PE16x | E2.6% | n/a | Capital Goods | ||
BAND | US$17.00 | -9.1% | 41.4% | US$467.7m | US$23.00 | PS0.6x | E73.8% | n/a | Telecom | ||
OXB | UK£3.45 | -11.5% | 103.7% | UK£365.6m | UK£5.30 | PS3.8x | E96.4% | n/a | Pharmaceuticals & Biotech | ||
STOK | US$8.33 | -22.0% | 40.2% | US$441.2m | US$23.88 | PS26.4x | E1.5% | n/a | Pharmaceuticals & Biotech | ||
PRCH | US$4.33 | -10.0% | 55.8% | US$438.3m | US$6.42 | PS1x | E3.4% | n/a | Software | ||
HGG | ₪25.31 | -10.9% | 71.4% | ₪1.6b | n/a | PE12.1x | n/a | 0% | Real Estate Management and Development | ||
CANG | US$4.16 | -9.6% | 137.0% | US$434.2m | n/a | PE22.5x | n/a | 0% | Retail | ||
EBS | US$7.71 | -20.7% | 181.4% | US$417.8m | US$13.50 | PS0.4x | E117.1% | n/a | Pharmaceuticals & Biotech | ||
2370 | ر.س38.45 | -11.6% | 66.5% | ر.س1.5b | n/a | PE19.4x | n/a | n/a | Capital Goods | ||
KULR | US$1.89 | -11.3% | 1,320.0% | US$404.6m | US$4.22 | PS41.7x | E78.9% | n/a | Capital Goods | ||
A053030 | ₩18,100.00 | -8.4% | 59.3% | ₩576.4b | ₩30,700.00 | PS4.4x | S31.2% | n/a | Pharmaceuticals & Biotech | ||
CMPX | US$2.92 | -13.6% | 63.1% | US$401.8m | US$11.22 | PS472.7x | E54.3% | n/a | Pharmaceuticals & Biotech | ||
TKNO | US$7.45 | -10.0% | 115.9% | US$397.1m | US$10.67 | PS10.9x | E22.8% | n/a | Pharmaceuticals & Biotech | ||
AKBA | US$1.80 | -15.5% | 33.3% | US$392.7m | US$7.17 | PS2.3x | E56.3% | n/a | Pharmaceuticals & Biotech |